Drug Interactions between Cuprimine and niraparib
This report displays the potential drug interactions for the following 2 drugs:
- Cuprimine (penicillamine)
- niraparib
Interactions between your drugs
penicillAMINE niraparib
Applies to: Cuprimine (penicillamine) and niraparib
Consumer information for this interaction is not currently available.
MONITOR: The concomitant use of myelosuppressive, immunosuppressive, or cytotoxic agents may potentiate and/or prolong the bone marrow toxicity associated with niraparib. Thrombocytopenia, anemia, neutropenia, and/or pancytopenia have all been observed with niraparib during clinical trials, especially during the initial phase of treatment. Additionally, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib. Some cases were fatal, and the duration of therapy with niraparib in patients who developed MDS/AML varied from less than 1 month to approximately 6 years. All patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.
MANAGEMENT: Caution is advised if niraparib is prescribed with other myelosuppressive, immunosuppressive, or cytotoxic agents. Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1 or less). Complete blood counts should be monitored as recommended in the product labeling and any relevant institutional protocols. Recommendations for dose adjustments as well as treatment interruption and discontinuation can also be found in the product labeling for serious hematologic adverse reactions. If hematological toxicities have not resolved within 4 weeks after interruption, discontinue niraparib and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue niraparib. Patients should be advised to contact their physician if they experience pale skin, weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.
References
- "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc. (2023):
- "Product Information. Zejula (niraparib)." GlaxoSmithKline (2023):
- "Product Information. Zejula (niraparib)." GlaxoSmithKline Inc (2023):
- "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc (2023):
- "Product Information. Zejula (niraparib)." GlaxoSmithKline Australia Pty Ltd (2023):
- "Product Information. Zejula (niraparib)." GlaxoSmithKline UK Ltd (2023):
Drug and food interactions
penicillAMINE food
Applies to: Cuprimine (penicillamine)
You may experience reduced absorption of penicillAMINE in the presence of food. The effectiveness of the antibiotic may be reduced. PenicillAMINE should be administered one hour before or two hours after meals and at least one hour apart from any other drug, food, or milk. This will make it easier for your body to absorb the medication.
penicillAMINE food
Applies to: Cuprimine (penicillamine)
PenicillAMINE and multivitamin with minerals should not be taken orally at the same time. Products that contain magnesium, aluminum, calcium, iron, and/or other minerals may interfere with the absorption of penicillAMINE into the bloodstream and reduce its effectiveness. You should take multivitamin with minerals at least 2 hours before or 2 hours after the penicillAMINE dose, penicillAMINE should be taken at least 2 hours before and not less than 6 hours after Suprep Bowel Prep (magnesium/potassium/sodium sulfates), or penicillAMINE and multivitamin with minerals should be taken as directed by your healthcare provider. Talk to your healthcare provider if you are unsure whether your medications contain something that could potentially interact or if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.